close
MENU
Hot Topic Hawke’s Bay
Hot Topic Hawke’s Bay
1 mins to read

Volpara raises $A7m in discounted placement

The capital raising would lift Volpara's proforma cash-on-hand to $A16.6 million

Jonathan Underhill
Tue, 22 Nov 2016

Volpara Health Technologies, the Wellington-based, ASX-listed digital health company, has raised $A7 million in a discounted placement and plans to raise a further $A3.7 million in an entitlement offer to shareholders.

The company, which is focused on early detection of breast cancer, sold 11.6 million shares at 60Ac apiece to institutional investors, a 28% discount to their last trading price. It is now undertaking a one-for-20 non-renounceable entitlement offer at the same price.

The capital raising would lift Volpara's proforma cash-on-hand to $A16.6 million from a closing cash position of $A6.4 million as at September 30, the company said in a statement.

Proceeds will be used "to accelerate the business development and sales of the company's products by growing the global sales team and increasing focus on product development, and to supplement working capital to support the rollout of VolparaEnterprise, its software as a service (SaaS) subscription-based model," it said.

The company posted its first-half results this month in its debut as a listed company. Total revenue climbed 4.8% to $1.2 million, while operating expenses more than doubled to $5.4 million, resulting in a wider loss of $4.7 million from $2.1 million.

The company first listed on the ASX in April, having raised about A$10 million selling shares at 50 Australian cents each. The shares recently traded at 76Ac, down 9% today but up 67% this year.

About 75 million women each year are screened for breast cancer globally, including 40 million in the US. Volpara's proprietary software has been used to analyse the mammograms of over nine million women to date.

Working in Volpara's favour is the fact it's operating in a large, high growth market with the incidence of breast cancer expected to double by 2030. It also holds extensive, clinically validated, intellectual property patents on its core VolparaDensity software and there are high barriers to entry for any newcomers into the market.​

(BusinessDesk)

Jonathan Underhill
Tue, 22 Nov 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Volpara raises $A7m in discounted placement
63322
false